Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy

Acta Oncologica

Volumn 35, Issue 2, 1996, Pages 213-219

  Stratford, Michael R L ^a   Dennis, Madeleine F ^a   Hoskin, Peter J ^a   Saunders, Michele I ^a   Hodgkiss, Richard J ^a   Rojas, Anamaria ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIOSENSITIZATION;

EID: 0029989613     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609098504     Document Type: Article

References (15)

1. Chaplin DJ, Horsman MR, Aoki DS. Nicotinamide, Fluosol DA and carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br J Cancer 1991; 63: 109-13.
2. Horsman MR, Chaplin DJ, Brown JM. Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat Res 1987; 109: 479-89.
3. Kjellen E, Joiner MC, Collier JM, Johns H, Rojas A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated x-ray treatments. Radiother Oncol 1991; 22: 81-91.
4. Rojas A. ARCON: accelerated radiotherapy with carbogen and nicotinamide. Br J Radiol 1992; (Suppl. 24): 174-8.
5. Horsman MR, Hoyer M, Honess DJ, Dennis IF, Overgaard J. Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother Oncol 1993; 27; 131-9.
6. Rojas A, Hodgkiss RJ, Stratford MRL, Dennis MF, Johns H. Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. Br J Cancer 1993; 68: 1115-21.
7. Hawkins DR. Treatment of schizophrenia based on the medical model. J Schizophrenia 1968; 2: 3-10.
8. 3 therapy for schizophrenia. Can Psychiat Ass J 1971; 16: 499-504.
9. Green RG. Subclinical pellagra: its diagnosis and treatment. Schizophrenia 1970; 2: 70-9.
10. Vague P, Picq R, Bernal M, Lassman-Vague V, Vialettes B. Effect of nicotinamide on the residual insulin secretion in type I (insulin-dependent) diabetic patients. Diabetologia 1989; 32: 316-21.
11. Zackheim HS, Vasily DB, Westphal ML, Hastings CW. Reactions to niacinamide. J Am Acad Dermatol 1981; 4: 736-7.
12. Stratford MRL, Rojas A, Hall DW, et al. Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. Radiother Oncol 1992; 25: 37-42.
13. Stratford MRL, Dennis MF. High-performance liquid chromatographic determination of nicotinamide and its metabolites in human and murine plasma and urine. J Chromatogr 1992; 582: 145-51.
14. Zackrisson B, Franzén L, Henriksson R, et al. Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON). Acta Oncol 1994; 33: 377-81.
15. Hoskin PJ, Stratford MRL, Saunders MI, Hall DW, Dennis MF, Rojas A. Administration of nicotinamide during CHART: pharmacokinetics, dose escalation and clinical toxicity. Int J Radiat Oncol Biol Phys 1995; 32: 1111-9.